Cambridge, UK - 14M Genomics (“14MG”) and The European Organisation for Research and Treatment of Cancer (“EORTC”) today announce the delivery of initial genomic mutation analyses conducted on newly diagnosed cancer patients as part of the EORTC Screening Patients for Efficient Clinical Trial Access (SPECTA) programme. The first SPECTA project, SPECTAcolor, focuses on the diagnosis [...]

Will work with Walgreens Boots Alliance in supporting Biobank 6 August 2015 (Brussels, Belgium) - The Dennis & Mireille Gillings Foundation has pledged €1 million to the European Organisation for Research and Treatment of Cancer (EORTC) Research Fund to help fight cancer. Part of the donation will support the SPECTAcolor Biobank, a tumor tissue sample Biobank and [...]

The EORTC-ETOP cooperation has now successfully given rise to SPECTAlung, the second SPECTA platform following SPECTAcolor. Our understanding of tumor biology has improved and continues to expand at a rapid pace, and this has opened new opportunities for cancer clinical trials, particularly for thoracic tumors. The identification and molecular alterations in the cancer and the [...]

Cambridge, UK: 10th March 2015. 14M Genomics (“14MG”) and the European Organisation for Research and Treatment of Cancer (“EORTC”) announced today a collaboration to use genomic diagnostic profiles to facilitate enrolment into next generation cancer clinical trials.   14MG will analyse patterns of genomic variation on newly diagnosed patients with colorectal, thoracic, brain and skin cancers [...]

Venue: Antwerp, Belgium Venue Thursday 22nd October : EORTC Task Forces meeting and SPECTAcolor steering committee. The Task Force meetings are open for everyone (academic investigators, young investigators, …), except for the representatives of pharmaceutical companies. Please note that these meetings are taking place at the Antwerp hospital. Transportation with bus are organized between the [...]

The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms are actively being developed and will be launched soon.